These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 21419858)
21. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282 [TBL] [Abstract][Full Text] [Related]
22. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Singleton PA; Moreno-Vinasco L; Sammani S; Wanderling SL; Moss J; Garcia JG Am J Respir Cell Mol Biol; 2007 Aug; 37(2):222-31. PubMed ID: 17395891 [TBL] [Abstract][Full Text] [Related]
23. The sphingosine-1-phosphate receptor agonist FTY720 and its phosphorylated form affect the function of CD4+CD25+ T cells in vitro. Liu Y; Jiang J; Xiao H; Wang X; Li Y; Gong Y; Huang Y Int J Mol Med; 2012 Jul; 30(1):211-9. PubMed ID: 22576630 [TBL] [Abstract][Full Text] [Related]
24. Modulating sphingosine 1-phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis. Hemdan NY; Weigel C; Reimann CM; Gräler MH Eur J Immunol; 2016 Dec; 46(12):2767-2777. PubMed ID: 27683081 [TBL] [Abstract][Full Text] [Related]
26. Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model. Schuhmann MK; Bittner S; Meuth SG; Kleinschnitz C; Fluri F Int J Mol Sci; 2015 Dec; 16(12):29454-66. PubMed ID: 26690412 [TBL] [Abstract][Full Text] [Related]
27. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Miron VE; Jung CG; Kim HJ; Kennedy TE; Soliven B; Antel JP Ann Neurol; 2008 Jan; 63(1):61-71. PubMed ID: 17918267 [TBL] [Abstract][Full Text] [Related]
28. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival. Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829 [TBL] [Abstract][Full Text] [Related]
29. FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl. Wang L; Chiang ET; Simmons JT; Garcia JG; Dudek SM Eur Respir J; 2011 Jul; 38(1):78-88. PubMed ID: 21071472 [TBL] [Abstract][Full Text] [Related]
30. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator. Ter Braak M; Claas RF; Hegen B; Labocha S; Ferreirós N; Pfeilschifter J; Huwiler A; van Echten-Deckert G; Meyer Zu Heringdorf D Biochem Pharmacol; 2011 Mar; 81(5):617-25. PubMed ID: 21163254 [TBL] [Abstract][Full Text] [Related]
31. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Shea BS; Brooks SF; Fontaine BA; Chun J; Luster AD; Tager AM Am J Respir Cell Mol Biol; 2010 Dec; 43(6):662-73. PubMed ID: 20081052 [TBL] [Abstract][Full Text] [Related]
32. Sphingosine-1-phosphate receptor 2 protects against anaphylactic shock through suppression of endothelial nitric oxide synthase in mice. Cui H; Okamoto Y; Yoshioka K; Du W; Takuwa N; Zhang W; Asano M; Shibamoto T; Takuwa Y J Allergy Clin Immunol; 2013 Nov; 132(5):1205-1214.e9. PubMed ID: 24021572 [TBL] [Abstract][Full Text] [Related]
33. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists. Clemens JJ; Davis MD; Lynch KR; Macdonald TL Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878 [TBL] [Abstract][Full Text] [Related]
35. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Ubai T; Azuma H; Kotake Y; Inamoto T; Takahara K; Ito Y; Kiyama S; Sakamoto T; Horie S; Muto S; Takahara S; Otsuki Y; Katsuoka Y Anticancer Res; 2007; 27(1A):75-88. PubMed ID: 17352219 [TBL] [Abstract][Full Text] [Related]
36. Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies? Köhne A; Stettner M; Jangouk P; Dehmel T; Hartung HP; Lehmann HC; Kieseier BC Arch Neurol; 2012 Oct; 69(10):1280-9. PubMed ID: 22751954 [TBL] [Abstract][Full Text] [Related]
37. Topical treatment targeting sphingosine-1-phosphate and sphingosine lyase abrogates experimental allergic rhinitis in a murine model. Kleinjan A; van Nimwegen M; Leman K; Hoogsteden HC; Lambrecht BN Allergy; 2013 Feb; 68(2):204-12. PubMed ID: 23253209 [TBL] [Abstract][Full Text] [Related]
38. FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation. Mencl S; Hennig N; Hopp S; Schuhmann MK; Albert-Weissenberger C; Sirén AL; Kleinschnitz C J Neuroimmunol; 2014 Sep; 274(1-2):125-31. PubMed ID: 25081505 [TBL] [Abstract][Full Text] [Related]
39. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Chiba K Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022 [TBL] [Abstract][Full Text] [Related]
40. Treatment with the sphingosine-1-phosphate analogue FTY 720 reduces loss of plasma volume during experimental sepsis in the rat. Lundblad C; Axelberg H; Grände PO Acta Anaesthesiol Scand; 2013 Jul; 57(6):713-8. PubMed ID: 23683126 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]